OpenLB
Open Library of Bioscience
Advanced Search
Current opinion in infectious diseases
10 01, 2023;36 (5): 379-384.

The disease burden of respiratory syncytial virus in Infants.

Alasdair P S Munro, Federico Martinón-Torres, Simon B Drysdale, Saul N Faust
Author Information
  1. Alasdair P S Munro: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust.
  2. Federico Martinón-Torres: Translational Paediatrics and Infectious Diseases, Hospital Clínico Universitario and Universidad de Santiago de Compostela.
  3. Simon B Drysdale: Centre for Neonatal and Paediatric Infection, Institute for Infection and Immunity, St George's, University of London.
  4. Saul N Faust: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust.
PMID: 37610444 DOI: 10.1097/QCO.0000000000000952

Abstract

PURPOSE OF REVIEW: To describe the current global burden of respiratory syncytial virus (RSV) in infants and its implications for morbidity, health resources and economic costs.
RECENT FINDINGS: New prophylactic therapies are on the horizon for RSV in the form of long-acting monoclonal antibodies suitable for healthy infants and maternal immunizations.
SUMMARY: Despite being responsible for significant global infant morbidity and mortality, until recently there have been no effective therapeutics available for healthy infants to protect them from RSV. Several new drugs are likely to be available within the next few years which could help relieve a huge burden on healthcare systems over the coming winters.

References

  1. N Engl J Med. 1987 Aug 6;317(6):329-34 [PMID: 3600729]
  2. Virus Res. 1985 Mar;2(2):157-73 [PMID: 3993233]
  3. PLoS One. 2014 Aug 18;9(8):e105543 [PMID: 25133576]
  4. Lancet. 2017 Jan 14;389(10065):211-224 [PMID: 27549684]
  5. Euro Surveill. 2019 Jan;24(1): [PMID: 30621817]
  6. Curr Med Res Opin. 2010 Sep;26(9):2175-81 [PMID: 20666690]
  7. Pediatrics. 2009 Dec;124(6):e1072-80 [PMID: 19933730]
  8. Epidemiology. 2019 Nov;30(6):918-926 [PMID: 31469696]
  9. BMC Infect Dis. 2021 Aug 2;21(1):730 [PMID: 34340679]
  10. J Infect. 2019 Jun;78(6):468-475 [PMID: 30817978]
  11. J Glob Health. 2015 Dec;5(2):020416 [PMID: 26682048]
  12. Arch Dis Child. 2003 Oct;88(10):922-6 [PMID: 14500316]
  13. J Infect Dis. 2022 Aug 15;226(Suppl 2):S225-S235 [PMID: 35968875]
  14. Lancet. 2022 May 28;399(10340):2047-2064 [PMID: 35598608]
  15. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189 [PMID: 36634694]
  16. ERJ Open Res. 2022 May 30;8(2): [PMID: 35651366]
  17. Lancet. 2022 Nov 12;400(10364):1663-1665 [PMID: 35843260]
  18. Sci Rep. 2021 Apr 26;11(1):8953 [PMID: 33903695]
  19. Pediatr Pulmonol. 2010 Jun;45(6):578-84 [PMID: 20503283]
  20. BMC Infect Dis. 2016 May 31;16:236 [PMID: 27246848]
  21. J Pediatr. 1976 Jul;89(1):11-5 [PMID: 180274]
  22. J Virol. 2005 Jan;79(2):1113-24 [PMID: 15613339]
  23. Rand Health Q. 2022 Nov 14;10(1):2 [PMID: 36484078]
  24. N Engl J Med. 2023 Apr 20;388(16):1451-1464 [PMID: 37018474]
  25. PLoS One. 2018 Nov 15;13(11):e0206474 [PMID: 30439987]
  26. BMC Infect Dis. 2014 Dec 16;14:694 [PMID: 25510622]
  27. J Infect Dis. 2020 Oct 7;222(Suppl 7):S680-S687 [PMID: 32227101]
  28. PLoS One. 2014 Feb 26;9(2):e89186 [PMID: 24586581]
  29. Am J Med. 1981 Mar;70(3):670-6 [PMID: 6259940]
  30. Open Forum Infect Dis. 2021 Mar 30;8(7):ofab159 [PMID: 34337092]
  31. J Infect Dis. 2022 Aug 12;226(Suppl 1):S22-S28 [PMID: 35023567]
  32. J Microbiol Immunol Infect. 2016 Oct;49(5):737-742 [PMID: 25442868]
  33. Epidemiol Infect. 2022 Feb 02;150:e45 [PMID: 35105415]
  34. J Clin Pathol. 1970 Feb;23(1):7-18 [PMID: 4909103]
  35. J Pediatr. 1981 Jul;99(1):100-3 [PMID: 7252646]
  36. Sci Immunol. 2016 Dec 16;1(6): [PMID: 28111638]
  37. J Infect Dis. 2021 Mar 3;223(5):811-817 [PMID: 33350450]
  38. Eur J Pediatr. 2004 Jul;163(7):359-63 [PMID: 15106003]
  39. J Infect Dis. 2022 Mar 15;225(6):1100-1111 [PMID: 33346360]
  40. Euro Surveill. 2022 Apr;27(16): [PMID: 35451364]
  41. BMJ Open. 2016 Jun 02;6(6):e009337 [PMID: 27256085]
  42. Clin Microbiol Rev. 2017 Jan;30(1):277-319 [PMID: 27903593]
  43. J Virol. 2015 Apr;89(7):3444-54 [PMID: 25609811]
  44. BMC Med. 2020 Apr 6;18(1):82 [PMID: 32248817]
  45. J Clin Invest. 2014 May;124(5):2219-33 [PMID: 24713657]
  46. J Infect Dis. 2022 Aug 12;226(Suppl 1):S10-S16 [PMID: 33576788]
  47. N Engl J Med. 2009 Feb 5;360(6):588-98 [PMID: 19196675]
  48. Theor Popul Biol. 2016 Aug;110:78-85 [PMID: 27155294]
  49. Infect Dis Ther. 2016 Sep;5(3):271-98 [PMID: 27480325]

Grants

  1. /Department of Health

MeSH Term

Infant
Humans
Respiratory Syncytial Viruses
Cost of Illness
Antibodies, Monoclonal
Health Resources
Immunization

Chemicals

Antibodies, Monoclonal
Review Journal Article Research Support, Non-U.S. Gov't
Article has an altmetric score of 56

Word Cloud

Created with Highcharts 10.0.0burdenRSVinfantsglobalrespiratorysyncytialvirusmorbidityhealthyavailablePURPOSEOFREVIEW:describecurrentimplicationshealthresourceseconomiccostsRECENTFINDINGS:Newprophylactictherapieshorizonformlong-actingmonoclonalantibodiessuitablematernalimmunizationsSUMMARY:DespiteresponsiblesignificantinfantmortalityrecentlyeffectivetherapeuticsprotectSeveralnewdrugslikelywithinnextyearshelprelievehugehealthcaresystemscomingwintersdiseaseInfants

Similar Articles

Cited By (8)